Week 23 · June 2026
June 2026
A curated, open repository of psychedelic clinical trials, research, and regulatory updates. 984 entries — updated weekly.
Read this week's full issue →Regulatory · U.S. Food and Drug Administration
RFK, Jr., puts psychedelics on fast track to FDA review and approval
The FDA announced it is fast-tracking review and approval for three companies studying psilocybin and methylone for depression and PTSD, and approved a phase 1 clinical trial of noribogaine for alcohol use disorder.
Read on General News →Featured This Week
General News · 2026-06-07
Psilocybin
Observational
The center focuses on exploring psilocybin for various psychiatric and behavioral disorders, with demonstrated safety in regulated settings and potential benefits for anxiety in cancer patients and smoking cessation.
General News · 2026-06-07
MDMA
Phase 2
The VA launched a new randomized controlled trial of MDMA-assisted therapy for PTSD and alcohol use disorder in U.S. veterans; it will enroll approximately 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and a control group.
MAPS.org · Thu, 23 Ap
Other
News
MAPS marks its 40th anniversary, having raised more than $150 million, supported 45 studies, trained 500+ therapists, and contributed to the first NDA submission for a psychedelic-assisted therapy. The organization also notes a new federal Executive Order directing agencies to expand psychedelic research and accelerate regulatory approval.
More from the Feed